Kynam Capital Management, LP, along with its general partner Kynam Capital Management GP, LLC, and Yue Tang, have filed a Schedule 13G with the United States Securities and Exchange Commission on January 10, 2024, indicating a significant ownership stake in Burning Rock Biotech Limited. The filing, dated December 31, 2023, reveals that the entities collectively hold 8,694,426 Class A Ordinary Shares, representing 10.19% of the class. The shares are reported to be beneficially owned with both sole and shared voting and dispositive power. The filing indicates that the shares were acquired in the ordinary course of business and not for the purpose of influencing control of the company. Burning Rock Biotech Limited, headquartered in Guangzhou, China, is the issuer of the securities in question. Kynam Capital Management and its associated entities are organized under the laws of Delaware, with Yue Tang, a U.S. citizen, serving as the Managing Member.

Kynam Capital Management, LP, along with its general partner Kynam Capital Management GP, LLC, and Yue Tang, have filed a Schedule 13G with the United States Securities and Exchange Commission on January 10, 2024, indicating a significant ownership stake in Burning Rock Biotech Limited. The filing, dated December 31, 2023, reveals that the entities collectively hold 8,694,426 Class A Ordinary Shares, representing 10.19% of the class. The shares are reported to be beneficially owned with both sole and shared voting and dispositive power. The filing indicates that the shares were acquired in the ordinary course of business and not for the purpose of influencing control of the company. Burning Rock Biotech Limited, headquartered in Guangzhou, China, is the issuer of the securities in question. Kynam Capital Management and its associated entities are organized under the laws of Delaware, with Yue Tang, a U.S. citizen, serving as the Managing Member.